At AbbVie, we partner to achieve two important outcomes: deliver innovative medicines and make a remarkable impact on people’s lives. 

AbbVie’s Partnering Day provides an opportunity to:

  • Meet with our senior research and partnership leadership teams from AbbVie External Innovations and R&D to discuss your ideas and research in a one-on-one setting

  • Learn about our strategy, therapeutic areas of interest, and approach(es) to partnering 

  • Share information about your company, pipeline, and discovery platforms with members of the AbbVie R&D organization and AbbVie External Innovations. 

*There is no fee to register for this event and/or participate in 1:1 meetings or the Pitch Deck Seminar. You may register to attend only the General Session presentations. 1:1 meetings must be approved/confirmed. Due to limited space, only up to 2 representatives from the same company may register.

 

All applications for 1:1 meetings must include non-confidential supporting materials such as slide decks, poster presentations, and/or research papers in English.

 

AbbVie Asia Capabilities:

  • Headquarters situated within most Asian countries and regions including but not limited to Japan, China, S. Korea, Singapore, etc. with full supporting commercial, regulatory, and medical affairs teams 

  • R&D site in Tokyo and global manufacturing facility in Singapore

  • Experienced in Asia cross-border deals

  • For more information on AbbVie’s partnering approach, please visit: AbbVie Partnering Site

 
 

AbbVie is seeking to explore exciting new cross-border licensing opportunities with innovative biotechs in Asia.  In addition to attending the General Session presentations, Japanese academic technology transfer offices, VCs and biotechs are also welcome to apply for 1:1 meetings with AbbVie senior executives. 1:1 meetings will take place after the General Session. 

Selection Criteria for 1:1 Partnering

• Companies must have applied for a 1:1 meeting in advance and have been approved

• Project proposals will be evaluated based on project stage, strategic fit (i.e., AbbVie’s five areas of therapeutic
interest), and differentiation

 
 

Tuesday, April 15, 2025

General Session

08:30 – 09:30 Registration & Light Refreshments

09:30 – 11:00 Overview of AbbVie’s Corporate Strategy and AbbVie’s External Innovation Strategy

- AbbVie S&E Overview

- AbbVie External Innovation

- AbbVie Commercial and Japan Strategy

- AbbVie Ventures

- Driving Innovation Within the Japan Healthcare Ecosystem: VC Panel Discussion

- Q&A

11:00 – 12:00 Networking Break

12:00 – 13:00 Pitch Deck Seminar

13:00 – 17:00 1:1 Partnering Meetings

*all times are Local Tokyo Time

 
 

Questions? Please email
wendy.tai@abbvie.com

 

For additional information on AbbVie’s partnering approach, please click here.

 
 
 
 

Pitch Deck Seminar
“Pitch Deck Seminar”, in collaboration with BioLabs, will provide useful insights on how to make your presentation more impactful and attractive for global VCs and pharmaceutical companies. 40 attendees in maximum from academic TTOs, entrepreneurs and biotech startups will be selected. Submissions for the seminar must be accompanied with non-confidential presentations, such as presentation slides, poster presentations, and/or research briefs in English.

Where/when is the event taking place? 
The event will take place in-person at the AbbVie Japan office located at 3-1-21, Shibaura, Minato-ku, 108-0023 in Tokyo on April 15, 2025. For more information on the venue/address, please click here.

Is there a registration or application fee involved? 
There is no fee to register for this event and/or participate in the Pitch Deck Seminar or 1:1 meetings.  We encourage all potential interested parties within the Asian Pacific life science ecosystem (i.e., biotechs, healthcare VCs, academic technology transfer offices) to attend/apply. Due to limited space, only up to 2 representatives from the same company may register. Vendors and service providers are not eligible to register.

May I attend the event onsite in Tokyo without applying for 1:1 Partnering?
Yes.  If you are from a biopharmaceutical company, VC or academic technology transfer office, you are invited to attend to listen to the General Session presentations and for general networking. Due to limited space, only up to 2 representatives from the same company may register. Vendors/service providers are not able eligible to join. To register to attend the event, please visit here.

Should I submit supporting documents with my application?
If you are interested in applying for a 1:1 meeting or attending the Pitch Deck Seminar, yes. Please click here to submit. If you are only attending the General Session, you do not need to submit supporting documents. Please be sure to attach non-confidential supporting materials such as slide decks, poster presentations and/or research papers as part of your application. 

Please do not submit any confidential information as any submitted information be treated as non-confidential. Of course, we will use this information only internally for evaluation purposes and will not further distribute.

What types of cross border deals are of interest to AbbVie?
Depending on the asset and stage of development, AbbVie is flexible and experienced in terms of potential deal structure types (i.e., in-licensing, co-development, co-commercial, etc.). 

Where can I find more information about AbbVie and its approach to partnering?
Please click here to visit the AbbVie Partnering Site.

Visit AbbVie News Center
Visit AbbVie LinkedIn
Visit Recent Nature Article (How AbbVie aims to transform lives with early-stage investments in breakthrough science)